Ab therapy of AML: native anti-CD33 Ab and drug conjugates.

Abstract

MAb have become an important treatment modality in cancer therapy.Genetically engineered chimeric and humanized Ab have demonstrated activity against a variety of tumors. While the humanized anti-CD33MAb lintuzumab has only modest single-agent activity against overt AML, it can eliminate minimal residual disease detectable by reverse transcription-PCR in acute promyelocytic leukemia. Targeted chemotherapy with the anti−CD33−calicheamicin construct gemtuzumab ozogamicin has produced remissions in patients with relapsed AML and appears promising when used in combination with standard chemotherapy in the treatment of newly diagnosed AML.

• Authors: J G Jurcic
• Journal: Cytotherapy (Cytotherapy) Vol. 10 Issue 1 Pg. 7-12 ( 2008) ISSN: 1477-2566 [Electronic] England
• PMID: 17917880 (Publication Type: Journal Article, Review)

Chemical References

• Aminoglycosides
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antigens, CD
• Antigens, Differentiation, Myelomonocytic
• CD33 protein, human
• Sialic Acid Binding Ig-like Lectin 3
• Gemtuzumab
• lintuzumab

Topics

• Aminoglycosides (administration & dosage, therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized (administration & dosage, therapeutic use)
• Antigens, CD (administration & dosage, therapeutic use)
• Antigens, Differentiation, Myelomonocytic (administration & dosage, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Gemtuzumab
• Humans
• Immunotherapy (methods)
• Leukemia, Myeloid, Acute (immunology, therapy)
• Sialic Acid Binding Ig-like Lectin 3